Description

Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease characterized by the progressive destruction of bile ducts, often leading to chronic liver disease and cirrhosis. Currently, there are only two FDA-approved treatments for PBC, but several promising therapies are in development.

This episode of EASL Studio:

  • Addresses the persistent challenge of managing pruritus in PBC.
  • Explores the collaboration between academia and industry in advancing treatments for rare diseases like PBC.
  • Speculates on what future treatment plans for PBC may look like.

Faculty

  • Ana Lleo (Moderator)
  • Phil Troke (GSK Representative)
  • Christophe Hezode (Gilead Representative)
  • Dimitar Tonev (IPSEN Representative)

This EASL Studio is supported by GSK, Gilead, and IPSEN.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments